Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, ...
Stories by SWNS on MSN
Brit first in Europe to receive new drug that 'attaches' to cancer cells
A Brit has become the first patient in Europe to trial a pioneering antibody drug that ‘attaches’ to cancer cells. Brian ...
Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself. The same treatments that can save patients from cancer may also r ...
A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form ...
Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic ...
A prescription medication that has been available in the U.S. since 1992 might have another significant benefit.
Safer Minimally Invasive Treatments in High-Risk & Comorbid Patients with Prostate Enlargement (BPH)
Leg-spinner Yuzvendra Chahal's maiden six-wicket for India as the hosts beat England by 75 runs in the third and final Twenty20 International ...
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.
No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results